Dear Editor,Sarcomas represent a heterogenous group of tumors accounting for about 1%of cancer in adults and 15%in children[1].However,despite adequate locoregional treatment,up to 40%of patients develop metastatic di...Dear Editor,Sarcomas represent a heterogenous group of tumors accounting for about 1%of cancer in adults and 15%in children[1].However,despite adequate locoregional treatment,up to 40%of patients develop metastatic disease.Drugs used in the advanced setting have very limited efficacy,with a response rate of<10%and progression-free survival of<4 months and are mainly used for palliative purposes[1].It is,therefore,important to monitor individual therapy responses to avoid inefficient therapy and unnecessary toxicity.Such monitoring is currently based on repeated CT imaging which may represent an important burden for patients with advanced disease[2].展开更多
To the editor Soft-tissue sarcomas(STS)represent a very heterogeneous group of rare tumors including more than 100 different subtypes[1].Surgery and neo/adjuvant radiation therapy represent the cornerstone of treatmen...To the editor Soft-tissue sarcomas(STS)represent a very heterogeneous group of rare tumors including more than 100 different subtypes[1].Surgery and neo/adjuvant radiation therapy represent the cornerstone of treatment for STS.However,despite an optimal resection of the tumor,up to 40%of patients will develop metastatic relapse and will die from the disease[1].Doxorubicin represents the first-line standard of care for patients with advanced disease since the 1970s,despite several attempts to identify better regimens.The median overall survival(OS)of patients with metastatic disease is<18 months and has only modestly improved over the past 20 years[2].展开更多
文摘Dear Editor,Sarcomas represent a heterogenous group of tumors accounting for about 1%of cancer in adults and 15%in children[1].However,despite adequate locoregional treatment,up to 40%of patients develop metastatic disease.Drugs used in the advanced setting have very limited efficacy,with a response rate of<10%and progression-free survival of<4 months and are mainly used for palliative purposes[1].It is,therefore,important to monitor individual therapy responses to avoid inefficient therapy and unnecessary toxicity.Such monitoring is currently based on repeated CT imaging which may represent an important burden for patients with advanced disease[2].
基金MSD(Merck Sharp and Dohme)AVENIR.Grant Number:HEART。
文摘To the editor Soft-tissue sarcomas(STS)represent a very heterogeneous group of rare tumors including more than 100 different subtypes[1].Surgery and neo/adjuvant radiation therapy represent the cornerstone of treatment for STS.However,despite an optimal resection of the tumor,up to 40%of patients will develop metastatic relapse and will die from the disease[1].Doxorubicin represents the first-line standard of care for patients with advanced disease since the 1970s,despite several attempts to identify better regimens.The median overall survival(OS)of patients with metastatic disease is<18 months and has only modestly improved over the past 20 years[2].
